1、A Novo Nordisk employee receiving a tour of our active construction project at our site in Kalundborg,Denmark.This project is part of our investment of more than DKK 80 billion in new active pharmaceutical ingredient facilities.These significant expansions aim to scale up production of life-changing

2、 treatments,including GLP-1-based medicines,to benefit many more people living with serious chronic diseases.FORM 20-F 2024Novo Nordisk A/S Novo Alle 1,2880 Bagsvrd,Denmark CVR no.24256790 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 20-F(Mark One)oREGISTRATION STATEMENT

3、PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934ORxANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December31,2024ORoTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934ORoSHELL COMPAN

4、Y REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934Commission File Number:333-82318NOVO NORDISK A/S(Exact name of Registrant as specified in its charter)Not applicableThe Kingdom of Denmark(Translation of Registrants name into English)(Jurisdiction of incorporation or orga

5、nization)Novo Alle 1DK-2880 BagsvrdDenmark(Address of principal executive offices)Karsten Munk KnudsenExecutive vice president and chief financial officerTel:+45 4444 8888E-mail:Novo Alle 1,DK-2880 Bagsvrd,Denmark(Name,Telephone,E-mail and Address of Company Contact Person)Securities registered or t

6、o be registered pursuant to Section 12(b)of the Act:Title of each class:Trading Symbol(s):Name of each exchange on which registered:B shares,nominal value DKK 0.10 eachNew York Stock Exchange*American Depositary Receipts,each representing one B ShareNVONew York Stock Exchange*Not for trading,but onl